StockNews.com Initiates Coverage on Fresenius Medical Care (NYSE:FMS)

Stock analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued to clients and investors on Saturday. The firm set a “strong-buy” rating on the stock.

FMS has been the topic of a number of other research reports. Truist Financial increased their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday. They issued a “buy” rating and a $25.60 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Fresenius Medical Care presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.30.

Fresenius Medical Care Stock Down 0.2 %

FMS stock opened at $21.29 on Friday. The stock has a 50-day simple moving average of $20.46 and a two-hundred day simple moving average of $20.23. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $12.49 billion, a PE ratio of 21.94, a PEG ratio of 0.97 and a beta of 0.91. Fresenius Medical Care has a twelve month low of $16.86 and a twelve month high of $22.76.

Hedge Funds Weigh In On Fresenius Medical Care

Several hedge funds and other institutional investors have recently modified their holdings of FMS. Allworth Financial LP grew its holdings in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after buying an additional 624 shares in the last quarter. Signaturefd LLC grew its position in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after buying an additional 672 shares during the period. Ritholtz Wealth Management lifted its position in Fresenius Medical Care by 2.5% during the 2nd quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock valued at $704,000 after acquiring an additional 895 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Fresenius Medical Care by 6.7% during the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after purchasing an additional 1,128 shares in the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.